Loading...
Target Audience: Clinicians treating people with HIV; clinical researchers monitoring rates of HIV drug resistance
Background and Objective
The IAS-USA last published recommendations regarding antiretroviral drug resistance testing in 2008 (NEJM JW HIV/AIDS Aug 2008 and Clin Infect Dis 2008; 47:266), and it regularly provides updates on drug resistance mutations. Now, an expert panel provides guidance on testing and monitoring for drug resistance based on recent changes in antiretroviral medications, frequency of transmitted drug resistance (TDR), and methods for detecting drug resistance.
Key Points
In resource-rich regions, the prevalence of TDR is about 10%, and similar TD…